CPAP Alternatives: Every Treatment Option for Sleep Apnea

CPAP (continuous positive airway pressure) remains the gold standard treatment for moderate to severe obstructive sleep apnea (OSA), and for good reason: when used consistently, it eliminates apneas nearly completely, reduces cardiovascular risk, and restores daytime alertness. The problem is that approximately 50 percent of CPAP users abandon the device within the first year. The reasons are consistent across studies: mask discomfort, claustrophobia, nasal dryness, noise, partner complaints, travel inconvenience, and the psychological burden of sleeping tethered to a machine every night for the rest of your life.

For the millions of people who cannot or will not tolerate CPAP, the question is not whether treatment is needed (untreated moderate to severe OSA carries significant cardiovascular and cognitive risks) but whether effective alternatives exist. The answer is nuanced: several alternatives work well for specific subsets of patients, but no single alternative matches CPAP's universal efficacy across all severities and all anatomical configurations of OSA. Choosing the right alternative requires understanding your specific apnea mechanism, severity, and anatomy.

Oral Appliance Therapy (Mandibular Advancement Devices)

Oral appliances, specifically mandibular advancement devices (MADs), are the most widely used CPAP alternative. A MAD is a custom-fitted dental device that holds the lower jaw forward during sleep, preventing the tongue and soft palate from collapsing into the airway. It looks similar to an orthodontic retainer or a sports mouthguard, though clinical-grade devices are substantially more sophisticated.

The American Academy of Sleep Medicine (AASM) recommends oral appliances as first-line therapy for mild to moderate OSA and as a second-line option for severe OSA in patients who refuse or cannot tolerate CPAP. Custom-fitted devices, made by a dentist trained in dental sleep medicine, are significantly more effective than over-the-counter "boil-and-bite" anti-snoring mouthpieces. The custom fit allows precise titration of jaw advancement, typically 60 to 70 percent of maximum protrusion, optimizing airway opening while minimizing jaw discomfort.

Effectiveness varies by severity. For mild OSA (AHI 5 to 15), oral appliances reduce the AHI by approximately 50 to 60 percent, often to normal levels. For moderate OSA (AHI 15 to 30), the reduction is typically 40 to 50 percent, which may or may not achieve a normal AHI but usually produces clinically meaningful improvement in symptoms. For severe OSA (AHI above 30), oral appliances are less reliably effective, reducing AHI by 30 to 40 percent, often leaving residual apnea that, while improved, may still be clinically significant.

Limitations and Side Effects

• Jaw pain or temporomandibular joint (TMJ) discomfort in the first weeks of use (usually resolves with adjustment)
• Potential long-term dental changes: bite shift, tooth movement, and altered occlusion with years of nightly use
• Not suitable for patients with insufficient teeth, severe TMJ disorder, or central sleep apnea
• Cost: $1,800 to $3,000 for a custom device, though many insurance plans now cover oral appliances

Positional Therapy

Approximately 50 to 60 percent of OSA patients have positional apnea, meaning their AHI is at least twice as high when sleeping on their back (supine) compared to sleeping on their side (lateral). For these patients, preventing supine sleep can reduce AHI by 50 percent or more, sometimes to normal levels.

Positional therapy devices range from simple (a tennis ball sewn into the back of a sleep shirt, which makes supine sleeping uncomfortable) to sophisticated (wearable vibrating devices that deliver a gentle vibration when the wearer rolls onto their back, training a subconscious avoidance response). The Night Shift device and the Philips NightBalance are examples of FDA-cleared positional therapy devices that have demonstrated efficacy in clinical trials.

Positional therapy is most appropriate as a standalone treatment for mild positional OSA and as a complement to other treatments (oral appliance or CPAP at lower pressure) for moderate positional OSA. It is not sufficient as standalone treatment for severe OSA or for non-positional apnea.

Hypoglossal Nerve Stimulation (Inspire Therapy)

Inspire is an implantable device that stimulates the hypoglossal nerve, which controls the tongue, during sleep. A small generator implanted in the chest (similar to a pacemaker) delivers mild electrical stimulation to the nerve with each breath, causing the tongue to move forward and maintaining an open airway. The patient activates the device with a handheld remote before sleep and deactivates it upon waking.

The STAR trial (2014, New England Journal of Medicine) demonstrated that Inspire reduced the median AHI from 29.3 (severe) to 9.0 (mild) at 12 months. Five-year follow-up data showed sustained efficacy with high patient satisfaction and adherence rates exceeding 80 percent.

Inspire is FDA-approved for patients with moderate to severe OSA (AHI 15 to 65) who have failed or cannot tolerate CPAP and who do not have complete concentric collapse of the palate (determined by drug-induced sleep endoscopy, or DISE). The procedure is minimally invasive, performed under general anesthesia, and typically involves one night in the hospital.

The primary barriers are cost ($30,000 to $40,000 for the device and implantation, though most insurance plans now cover it for qualifying patients) and surgical candidacy. Not all anatomical patterns of airway collapse respond to tongue-base stimulation, which is why the DISE evaluation is critical before proceeding.

Surgical Options

UPPP (Uvulopalatopharyngoplasty)

The most commonly performed surgery for OSA, UPPP removes excess tissue from the soft palate, uvula, and pharyngeal walls to widen the airway. Success rates vary widely: the procedure achieves a 50 percent or greater reduction in AHI in approximately 40 to 50 percent of unselected patients. Success rates improve to 60 to 70 percent when patients are carefully selected based on the specific site of airway collapse.

UPPP recovery is painful, typically requiring two weeks of a soft diet and significant throat discomfort. Long-term side effects can include velopharyngeal insufficiency (nasal regurgitation of liquids) and changes in voice quality. Because of the moderate success rate and significant recovery, UPPP has declined in popularity relative to newer options.

Maxillomandibular Advancement (MMA)

MMA surgery moves both the upper and lower jaws forward, dramatically enlarging the airway. It is the most effective surgical treatment for OSA, with success rates exceeding 85 percent in appropriately selected patients. However, it is also the most invasive, involving jaw osteotomies (controlled fractures), hardware fixation, and a recovery period of four to six weeks with jaw wiring or elastic traction.

MMA is typically reserved for severe OSA that has failed all other treatments, or for patients with craniofacial anatomy (recessed jaw, small airway) that makes them particularly likely to benefit from skeletal advancement.

Nasal Surgery

Nasal obstruction from a deviated septum, enlarged turbinates, or nasal valve collapse does not cause OSA on its own, but it can worsen OSA and reduce the effectiveness of CPAP (by increasing the pressure required). Septoplasty and turbinate reduction can improve nasal airflow sufficiently to make CPAP tolerable at lower pressures, which often improves adherence. As standalone OSA treatment, nasal surgery has limited efficacy.

Lifestyle Modifications

Weight loss is the most impactful lifestyle modification for OSA. Excess weight, particularly visceral and neck fat, narrows the airway and increases collapsibility. A 10 percent weight loss reduces AHI by approximately 26 percent on average, according to Peppard et al. (2000, JAMA). In some patients with mild to moderate OSA, weight loss alone can normalize the AHI.

Other evidence-supported lifestyle modifications include avoiding alcohol within three hours of bedtime (alcohol relaxes airway muscles and worsens apnea), smoking cessation (smoking causes airway inflammation and swelling), and avoiding sedative medications that suppress respiratory drive.

These modifications are important complements to device or surgical therapy but are rarely sufficient as standalone treatment for moderate to severe OSA. The exception is the patient whose OSA is primarily weight-driven and who achieves and maintains significant weight loss, in which case the apnea may resolve entirely.

Emerging Treatments

Several treatments are in clinical trials or early commercial availability. Excite OSA is a daytime neuromuscular stimulation device that strengthens the tongue muscles through 20-minute daily sessions, reducing their tendency to collapse during sleep. The eXciteOSA device received FDA clearance for mild OSA and snoring in 2021. Pharmacological treatments, including combinations of atomoxetine (a norepinephrine reuptake inhibitor) and oxybutynin (an antimuscarinic), have shown promise in reducing AHI by approximately 50 percent in early trials, though no drug is currently FDA-approved for OSA treatment.

Combination Therapy: When One Approach Is Not Enough

For many patients with moderate obstructive sleep apnea, single-modality treatment fails to reduce the apnea-hypopnea index (AHI) to the target range of fewer than five events per hour. This is where combination therapy becomes relevant — pairing two or more interventions that address different anatomical or physiological contributors to airway collapse. The most well-studied combination is a mandibular advancement device (MAD) plus positional therapy. Since supine sleeping increases AHI by 50 to 100 percent in most patients compared to lateral sleeping, wearing a MAD while also using a positional device that prevents supine sleep can reduce AHI by 70 to 85 percent — comparable to CPAP adherence rates in many studies.

Weight loss combined with oral appliance therapy is another evidence-based pairing. A 10 percent reduction in body weight reduces AHI by approximately 26 percent on average, according to a meta-analysis in the journal Sleep Medicine Reviews. When combined with a custom-fitted MAD that advances the mandible by 60 to 70 percent of maximum protrusion, the cumulative effect often achieves the same AHI reduction as CPAP for patients with moderate OSA (AHI 15-30). The advantage of this approach is sustainability — weight loss, once achieved, provides a permanent reduction in soft tissue volume around the airway, while the MAD addresses the residual anatomical narrowing that weight loss alone does not resolve.

Myofunctional therapy — structured exercises targeting the muscles of the tongue, soft palate, and pharyngeal walls — has emerged as a complementary approach with growing evidence. A meta-analysis in the journal Sleep found that oropharyngeal exercises reduced AHI by approximately 50 percent in adults with mild to moderate OSA. The exercises are simple (tongue positioning, swallowing patterns, and palatal stretches) and require 15 to 20 minutes per day, but compliance drops significantly after three months without structured follow-up. When sustained, the muscular tone improvements from myofunctional therapy can make other treatments more effective by reducing the baseline collapsibility of the airway. Several sleep medicine practices now offer combination protocols that sequence myofunctional therapy first, then reassess AHI before fitting an oral appliance, reducing the advancement distance required and improving comfort.

Combination Therapy: When One Approach Is Not Enough

Sleep medicine increasingly recognizes that moderate-to-severe obstructive sleep apnea often requires a multi-modal treatment strategy rather than reliance on a single intervention. The most evidence-backed combination pairs a mandibular advancement device with positional therapy for patients whose apnea events are predominantly supine-dependent. Studies published in the Journal of Clinical Sleep Medicine show that this combination reduces the apnea-hypopnea index by 60-75% in appropriately selected patients — not quite matching CPAP's efficacy but approaching it with significantly higher adherence rates.

Weight loss combined with any mechanical therapy also shows compounding benefits. A 10% reduction in body weight typically reduces AHI by 25-30% on its own. When paired with a mandibular advancement device, the combined effect can bring moderate apnea into the mild range, which many sleep physicians consider an acceptable treatment outcome given the improved quality of life. The challenge is that weight loss takes months to achieve while apnea causes damage nightly, so mechanical therapy serves as the bridge during the weight reduction period.

For patients with both obstructive and central apnea components — a pattern seen in roughly 15% of sleep apnea patients — combination therapy is particularly important because no single alternative to CPAP addresses both mechanisms. Positional therapy and oral appliances target the obstructive component, while supplemental oxygen or adaptive servo-ventilation may be needed for the central component. This complexity underscores why a board-certified sleep medicine specialist, rather than a general practitioner or dentist alone, should coordinate care for patients seeking CPAP alternatives.

Insurance Coverage and Cost Considerations

The financial landscape of CPAP alternatives is inconsistent and often frustrating for patients. CPAP machines and supplies enjoy well-established insurance coverage pathways — most plans cover them after a qualifying sleep study, with out-of-pocket costs typically ranging from $50-$200 with insurance. Mandibular advancement devices, despite strong clinical evidence, face more variable coverage. Custom devices from a dental sleep specialist cost $1,800-$3,000 out of pocket, though medical insurance increasingly covers them when documented as a treatment for diagnosed obstructive sleep apnea.

Inspire therapy represents the most expensive alternative, with total costs including surgery, device, and follow-up ranging from $30,000-$50,000. Most commercial insurers now cover Inspire for patients who meet specific criteria: moderate-to-severe OSA, BMI below 35, documented CPAP failure, and a drug-induced sleep endoscopy showing non-concentric collapse of the airway. Medicare has covered Inspire since 2020, though individual Medicare Advantage plans may impose additional requirements. Patients considering Inspire should verify coverage before proceeding and request a pre-authorization in writing.

Evaluating Effectiveness: What the Clinical Metrics Tell You

When comparing CPAP alternatives, the most important outcome metric is the post-treatment apnea-hypopnea index (AHI) — the number of breathing disruptions per hour of sleep. CPAP, when used consistently, reduces AHI to below five events per hour in over 95 percent of patients regardless of baseline severity. No alternative matches this efficacy across all severity levels, which is why CPAP remains the gold standard. However, the operative phrase is "when used consistently." CPAP adherence rates — defined as using the device for at least four hours per night on 70 percent of nights — hover around 50 percent in real-world studies. An alternative that reduces AHI to 10 events per hour but is actually used every night may produce better health outcomes than a CPAP that reduces AHI to 3 but sits on the nightstand five nights a week.

Beyond AHI, oxygen desaturation index (ODI) and minimum oxygen saturation (SpO2 nadir) provide additional information about treatment effectiveness that is particularly relevant for cardiovascular risk. A treatment that reduces AHI but does not adequately prevent oxygen desaturation below 88 percent may not fully protect against the hypertension, arrhythmia, and stroke risk associated with untreated OSA. When evaluating any alternative therapy, request both AHI and SpO2 data from your sleep study, not just the composite AHI number. Some oral appliances, for instance, reduce obstructive apneas effectively but are less effective at eliminating hypopneas (partial airway obstruction), which can still produce clinically significant oxygen desaturation events.

Positional Therapy for Mild to Moderate Sleep Apnea

For the estimated 50 to 60 percent of sleep apnea patients whose breathing events occur predominantly in the supine position, positional therapy offers a non-invasive alternative that addresses the root mechanical cause. When sleeping on the back, gravity pulls the tongue and soft palate toward the posterior pharyngeal wall, narrowing or completely obstructing the airway. Sleeping on the side eliminates this gravitational collapse, which is why polysomnography studies frequently show a 50 to 80 percent reduction in apnea-hypopnea index (AHI) when positional apnea patients sleep laterally.

Modern positional therapy devices have evolved well beyond the tennis-ball-in-a-shirt approach. FDA-cleared devices like the Night Shift and the Philips NightBalance use vibrotactile feedback — gentle vibrations that increase in intensity when the wearer rolls onto their back — to train lateral sleeping without producing full awakenings. Clinical studies show that these devices reduce supine sleep time by 80 to 95 percent and lower AHI by an average of 50 percent in position-dependent patients. However, positional therapy is not appropriate for patients with severe sleep apnea or those whose AHI remains elevated regardless of sleep position — a distinction that requires a formal sleep study to determine, not self-diagnosis based on subjective sleeping position awareness.

Oral Appliance Therapy: Effectiveness and Limitations

Mandibular advancement devices (MADs) — custom-fitted oral appliances that reposition the lower jaw forward during sleep — represent the most widely prescribed CPAP alternative for mild to moderate obstructive sleep apnea. These devices work by physically advancing the mandible 6 to 10 millimeters forward, which tensions the genioglossus muscle and prevents the tongue from collapsing into the airway. The American Academy of Sleep Medicine endorses MADs as a first-line treatment for mild to moderate sleep apnea and as a second-line option for severe cases where CPAP is not tolerated.

Custom-fitted MADs fabricated by a sleep dentist consistently outperform over-the-counter boil-and-bite devices in both AHI reduction and patient compliance. Studies published in the Journal of Clinical Sleep Medicine show that custom devices reduce AHI by an average of 50 to 70 percent, compared to 30 to 40 percent for OTC alternatives. The key limitation is that oral appliances do not work for everyone — approximately 30 percent of patients do not achieve clinically significant AHI reduction regardless of jaw advancement degree. Predictors of success include lower baseline AHI, younger age, lower BMI, and a predominantly supine apnea pattern. Patients with central sleep apnea or mixed apnea are not candidates for MAD therapy.

How to Choose

• Mild OSA with positional component: Oral appliance or positional therapy (or both). Lifestyle modifications as foundation.
• Moderate OSA, CPAP-intolerant: Custom oral appliance as first-line alternative. Inspire evaluation if oral appliance is insufficient or not tolerated.
• Severe OSA, CPAP-intolerant: Inspire evaluation (if anatomy is suitable). MMA surgery for candidates with favorable craniofacial anatomy. Combination therapy (oral appliance plus positional therapy) as an interim measure.
• Any severity with significant overweight: Weight loss program alongside device therapy. Weight loss is the only intervention that can potentially cure OSA rather than manage it.

The critical message is that abandoning CPAP should not mean abandoning treatment. Untreated moderate to severe OSA increases the risk of hypertension, stroke, heart attack, atrial fibrillation, type 2 diabetes, motor vehicle accidents, and cognitive decline. If you have tried CPAP and cannot use it, you have options. None of them is as universally effective as CPAP, but for many patients, a well-chosen alternative provides treatment that is effective enough, and actually used, which is the combination that produces real health outcomes.